PR Newswire BiotechOriginal article
New Progress -- XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson's Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment
Phase 1positiveXellSmart off-the-shelf cell therapyPositive
AI Analysis
Summary
XellSmart presented Phase I data for its off-the-shelf cell therapy for Parkinson's disease at the MDS Congress and announced completion of blinded Phase II enrollment. The provided text is truncated, so detailed results are not available.
Clinical Trial Data
Phase
Phase 1/Phase 2
Outcome Details
Phase I results presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS); blinded Phase II enrollment completed. Article excerpt is truncated and gives no detailed efficacy or safety data.
Importance:5/10
Sentiment:
0.50
Parkinson's diseasecell therapyoff-the-shelfPhase 1Phase 2MDS Congressenrollment completeneurology
Read the original article
Published by PR Newswire Biotech on October 18, 2026 4:27 AM